The Xoft System is cleared by the U.S. Food and Drug Administration, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including NMSC, early-stage breast cancer, and gynecological cancers.ABOUT ICAD, INC Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com. ABOUT SANTA CLARITA AND SHERMAN OAKS RADIATION THERAPY CENTERS, PART OF THE US ONCOLOGY NETWORK Santa Clarita Radiation Therapy Center, of Valencia, CA and Sherman Oaks Radiation Therapy Center, of Sherman Oaks, CA are part of The US Oncology Network, which has more than 1,400 affiliated physicians with expertise in medical oncology, hematology, radiation oncology, gynecologic oncology, urology, oncology surgery and other specialties at more than 400 sites of care in 26 states, treating over 1.1 million patients annually. The Network provides strong and comprehensive practice management capabilities and value-based care expertise that are critical for practices navigating today's challenging healthcare landscape. The Network is supported by McKesson Specialty Health, an industry leader in solutions that empower the community patient care delivery system to advance the science, technology and quality of care. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "would", "could", "consider", "project", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2016, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
Contact:Media Inquiries:ARPRErin Bocherer, (855) 300-8209 firstname.lastname@example.org or Investor Relations:LifeSci AdvisorsJeremy Feffer, (917) 749-1494 email@example.com